PPARG and colorectal carcinoma: In HT-29 human CRC cells, the PPARγ agonist rosiglitazone was observed to exert a protective effect in healthy intestinal tissues exposed to radiation, improve tissue structure, reduce intestinal apoptosis, and block inflammatory signaling cascades.